Showing 1,301 - 1,320 results of 114,413 for search '(( 2 mean decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 2.02s Refine Results
  1. 1301
  2. 1302

    Loss of ALS2 results in decreased levels of the lysosome-dependent degradation of LC3 in fibroblasts. by Shinji Hadano (251529)

    Published 2010
    “…Fibroblasts derived from either wild-type (<i>Als2</i><sup>+/+</sup>) or <i>Als2</i><sup>−/−</sup> mice were incubated in a starvation medium with or without 0.5 µM chloroquine (CQ) for 6 hr. …”
  3. 1303

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  4. 1304

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  5. 1305
  6. 1306
  7. 1307
  8. 1308
  9. 1309

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  10. 1310
  11. 1311
  12. 1312
  13. 1313
  14. 1314
  15. 1315
  16. 1316
  17. 1317
  18. 1318
  19. 1319
  20. 1320